SWOG clinical trial number
SWOG-9238 (INT-0134) (GOG-134) (NCCTG-92-61-51)

A Randomized Study of Intravenous Taxol at Three Dose Levels and G-CSF at Two Dose Levels in Platinum-Resistant Ovarian Carcinoma, Phase III (Intergroup)

Closed
Phase
Published
Abbreviated Title
A Randomized Study of Intravenous Taxol at Three Dose Levels and G-CSF at Two Dose Levels in Platinum-Resistant Ovarian Carcinoma, Phase III (Intergroup)
Activated
01/15/1993
Closed
02/06/1995

Research committees

Gynecologic Cancer

Publication Information Expand/Collapse

2003

Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study

GA Omura;MF Brady;KY Look;HE Averette;JE Delmore;HJ Long;S Wadler;G Spiegel;SG Arbuck Journal of Clinical Oncology 21(15):2843-2848

2001

Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials

JM Unger;LE Flaherty;PY Liu;KS Albain;VK Sondak Cancer 91(6):148-1155

1996

A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): A Gynecologic Oncology Group, SWOG, NCCTG and ECOG study.

GA Omura;MF Brady;JE Delmore;HJ Long;KY Look;HE Averette;S Wadler;G Spiegel American Society of Clinical Oncology 15:280(#755)